The presence of Hashimoto thyroiditis lowers the risk of recurrence of BRAF mutation-positive or mutation-negative differentiated thyroid cancer. BRAF V600E mutation is a negative prognostic factor.
The drug combination, which received accelerated approval from the FDA for patients aged 6 years and older, is the only BRAF/MEK inhibitor okayed for use in pediatric patients.
Combining dabrafenib with trametinib markedly improved response rates and delayed progression over standard-of-care chemotherapy in pediatric BRAF V600-mutant low-grade glioma in a phase 2 trial.
New results from a phase 3 trial may shut the door on the addition of PD–1 or PD–ligand 1 inhibitors to the combination of BRAF and MEK inhibitors for the treatment of BRAF V600–mutated melanoma.